Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer TreatmentYuxiao Song, Bicheng Zhang, Yang Fu et al.|Frontiers in Immunology|2020Cited by 256
Predictive Biomarkers of Immune Checkpoint Inhibitors-Related ToxicitiesYa Xu, Bicheng Zhang, Yang Fu et al.|Frontiers in Immunology|2020Cited by 82
Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational InvestigationShicong Zhu, Jun Wang, Yang Fu et al.|Frontiers in Oncology|2020Cited by 57
Current status of the clinical use of PD-1/PD-L1 inhibitors: a questionnaire survey of oncologists in ChinaBicheng Zhang, Jun Wang, Yuxiao Song et al.|BMC Cancer|2020Cited by 23
The efficacy of immune checkpoint inhibitors is limited in elderly NSCLC: a retrospective efficacy study and meta-analysisJiaxin Yin, Bicheng Zhang, Jiazhuo Tang et al.|Aging|2023Cited by 14